These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 17668999)

  • 1. Development of synthetic biodegradable microparticulate vaccines: a roller coaster story.
    Johansen P; Martínez Gómez JM; Gander B
    Expert Rev Vaccines; 2007 Aug; 6(4):471-4. PubMed ID: 17668999
    [No Abstract]   [Full Text] [Related]  

  • 2. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens.
    Jiang W; Gupta RK; Deshpande MC; Schwendeman SP
    Adv Drug Deliv Rev; 2005 Jan; 57(3):391-410. PubMed ID: 15560948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled release of PEI/DNA complexes from PLGA microspheres as a potent delivery system to enhance immune response to HIV vaccine DNA prime/MVA boost regime.
    Zhou X; Liu B; Yu X; Zha X; Zhang X; Wang X; Jin Y; Wu Y; Chen Y; Shan Y; Chen Y; Liu J; Kong W; Shen J
    Eur J Pharm Biopharm; 2008 Mar; 68(3):589-95. PubMed ID: 17950586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surface-modified biodegradable microspheres for DNA vaccine delivery.
    Keegan ME; Saltzman WM
    Methods Mol Med; 2006; 127():107-13. PubMed ID: 16988450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination.
    Wang D; Molavi O; Lutsiak ME; Elamanchili P; Kwon GS; Samuel J
    J Pharm Pharm Sci; 2007; 10(2):217-30. PubMed ID: 17706180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly (DL-lactide-co-glycolide) based delivery systems for vaccines and drugs.
    Dhiman N; Dutta M; Khuller GK
    Indian J Exp Biol; 2000 Aug; 38(8):746-52. PubMed ID: 12557904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation aspects of biodegradable polymeric microspheres for antigen delivery.
    Tamber H; Johansen P; Merkle HP; Gander B
    Adv Drug Deliv Rev; 2005 Jan; 57(3):357-76. PubMed ID: 15560946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microparticles for the delivery of DNA vaccines.
    O'Hagan DT; Singh M; Ulmer JB
    Immunol Rev; 2004 Jun; 199():191-200. PubMed ID: 15233735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodegradable PLGA particles for improved systemic and mucosal treatment of Type I allergy.
    Schöll I; Kopp T; Bohle B; Jensen-Jarolim E
    Immunol Allergy Clin North Am; 2006 May; 26(2):349-64, ix. PubMed ID: 16701149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biodegradable poly(DL-lactide-co-glycolide) microspheres.
    Eldridge JH; Staas JK; Tice TR; Gilley RM
    Res Immunol; 1992 Jun; 143(5):557-63; discussion 581. PubMed ID: 1439138
    [No Abstract]   [Full Text] [Related]  

  • 11. Factorial design, physicochemical characterisation and activity of ciprofloxacin-loaded PLGA nanoparticles for ocular use.
    Dillen K; Vandervoort J; Ludwig A
    J Control Release; 2005 Jan; 101(1-3):369-71. PubMed ID: 15822219
    [No Abstract]   [Full Text] [Related]  

  • 12. How to achieve sustained and complete protein release from PLGA-based microparticles?
    Giteau A; Venier-Julienne MC; Aubert-Pouëssel A; Benoit JP
    Int J Pharm; 2008 Feb; 350(1-2):14-26. PubMed ID: 18162341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microparticle delivery of plasmid DNA to mammalian cells.
    Hedley ML; Barman SP
    Methods Mol Biol; 2004; 245():265-86. PubMed ID: 14707387
    [No Abstract]   [Full Text] [Related]  

  • 14. Biodegradable microparticles as oral vaccines.
    O'Hagan DT; Jeffery H; Maloy KJ; Mowat AM; Rahman D; Challacombe SJ
    Adv Exp Med Biol; 1995; 371B():1463-7. PubMed ID: 7502838
    [No Abstract]   [Full Text] [Related]  

  • 15. Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice.
    Bivas-Benita M; Lin MY; Bal SM; van Meijgaarden KE; Franken KL; Friggen AH; Junginger HE; Borchard G; Klein MR; Ottenhoff TH
    Vaccine; 2009 Jun; 27(30):4010-7. PubMed ID: 19389445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local delivery of poly lactic-co-glycolic acid microspheres containing imatinib mesylate inhibits intracranial xenograft glioma growth.
    Benny O; Menon LG; Ariel G; Goren E; Kim SK; Stewman C; Black PM; Carroll RS; Machluf M
    Clin Cancer Res; 2009 Feb; 15(4):1222-31. PubMed ID: 19190128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained release of ciprofloxacin from an osteoconductive poly(DL)-lactide implant.
    Koort JK; Makinen TJ; Suokas E; Veiranto M; Jalava J; Tormala P; Aro HT
    Acta Orthop; 2008 Apr; 79(2):295-301. PubMed ID: 18484258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polylactide-co-glycolide (PLG) microparticles modify the immune response to DNA vaccination.
    Helson R; Olszewska W; Singh M; Megede JZ; Melero JA; O'Hagan D; Openshaw PJ
    Vaccine; 2008 Feb; 26(6):753-61. PubMed ID: 18191308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained delivery of endostatin improves the efficacy of therapy in Lewis lung cancer model.
    Wu J; Ding D; Ren G; Xu X; Yin X; Hu Y
    J Control Release; 2009 Mar; 134(2):91-7. PubMed ID: 19084038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses.
    Schlosser E; Mueller M; Fischer S; Basta S; Busch DH; Gander B; Groettrup M
    Vaccine; 2008 Mar; 26(13):1626-37. PubMed ID: 18295941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.